+2,684.0%
SNDK vs GSK
+31.2%
+2,652.8%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +11.9% | -1.9% | +13.8% | +11.5% |
| 7D | +17.2% | -1.8% | +19.0% | +16.8% |
| 30D | +28.8% | -2.2% | +31.0% | +28.5% |
| 3M | -1.1% | -1.8% | +0.7% | -1.8% |
| 6M | +190.5% | -10.6% | +201.1% | +199.3% |
| YTD | +633.0% | +4.4% | +628.6% | +600.2% |
| 1Y | +2,684.0% | +30.4% | +2,653.6% | +2,088.1% |
| All | +2,684.0% | +31.2% | +2,652.8% | +2,088.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling